Garg Pushkal, EVP and Chief R&D Officer at Alnylam Pharmaceuticals ($ALNY), sold shares on the open market 86 times over the past year, totaling $12.3 million. His most recent sale occurred on March 5, 2026. These activities rank him 964th among nearly 12,000 insiders by sale value in our database, above the average of $8.6 million across about 6.4 transactions per insider. Garg Pushkal made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 740 | $323.55 | 20,384.0000 | 134,684,000 | 3.50% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 106 | $319.03 | 23,981.0000 | 134,684,000 | 0.44% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 102 | $320.01 | 23,879.0000 | 134,684,000 | 0.43% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 215 | $320.81 | 23,664.0000 | 134,684,000 | 0.90% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 289 | $321.82 | 23,375.0000 | 134,684,000 | 1.22% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 350 | $323.01 | 23,025.0000 | 134,684,000 | 1.50% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 767 | $323.84 | 22,258.0000 | 134,684,000 | 3.33% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 272 | $324.88 | 21,986.0000 | 134,684,000 | 1.22% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 208 | $325.67 | 21,778.0000 | 134,684,000 | 0.95% | 0.00% |
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 654 | $322.33 | 21,124.0000 | 134,684,000 | 3.00% | 0.00% |
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 500 | $326.08 | 19,374.0000 | 134,684,000 | 2.52% | 0.00% |
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 510 | $324.59 | 19,874.0000 | 134,684,000 | 2.50% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 50 | $323.62 | 27,529.0000 | 134,684,000 | 0.18% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 277 | $325.63 | 27,155.0000 | 134,684,000 | 1.01% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 421 | $326.81 | 26,734.0000 | 134,684,000 | 1.55% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 353 | $327.67 | 26,381.0000 | 134,684,000 | 1.32% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 107 | $328.71 | 26,274.0000 | 134,684,000 | 0.41% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 182 | $329.71 | 26,092.0000 | 134,684,000 | 0.69% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 87 | $330.85 | 26,005.0000 | 134,684,000 | 0.33% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 101 | $331.93 | 25,904.0000 | 134,684,000 | 0.39% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 42 | $332.64 | 25,862.0000 | 134,684,000 | 0.16% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 355 | $316.74 | 25,507.0000 | 134,684,000 | 1.37% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 317 | $319.06 | 25,190.0000 | 134,684,000 | 1.24% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 640 | $320.48 | 24,550.0000 | 134,684,000 | 2.54% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 463 | $321.50 | 24,087.0000 | 134,684,000 | 1.89% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Stock Option (right to buy) | 10480 | $0.00 | 10,480.0000 | 134,684,000 | 9999.99% | 0.01% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Common Stock | 4769 | $0.00 | 27,579.0000 | 134,684,000 | 20.91% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 97 | $324.65 | 27,432.0000 | 134,684,000 | 0.35% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | M | Common Stock | 1908 | $0.00 | 27,437.0000 | 134,684,000 | 7.47% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 127 | $328.92 | 27,310.0000 | 134,684,000 | 0.46% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 2259 | $330.73 | 25,051.0000 | 134,684,000 | 8.27% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 1159 | $331.49 | 23,892.0000 | 134,684,000 | 4.63% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 942 | $332.48 | 22,950.0000 | 134,684,000 | 3.94% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 140 | $334.39 | 22,810.0000 | 134,684,000 | 0.61% | 0.00% |
| Feb. 27, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | M | Restricted Stock Units | 1908 | $0.00 | 0.0000 | 134,684,000 | 100.00% | 0.00% |
| Feb. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Common Stock | 4579 | $0.00 | 27,771.0000 | 134,684,000 | 19.74% | 0.00% |
| Feb. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 2242 | $310.08 | 25,529.0000 | 134,684,000 | 8.07% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 15 | $377.82 | 23,192.0000 | 134,684,000 | 0.06% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 19 | $375.65 | 23,207.0000 | 134,684,000 | 0.08% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 14 | $374.44 | 23,226.0000 | 134,684,000 | 0.06% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 3 | $372.46 | 23,240.0000 | 134,684,000 | 0.01% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 18 | $370.87 | 23,243.0000 | 134,684,000 | 0.08% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 40 | $369.48 | 23,261.0000 | 134,684,000 | 0.17% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 92 | $368.62 | 23,301.0000 | 134,684,000 | 0.39% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 41 | $367.40 | 23,393.0000 | 134,684,000 | 0.17% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 50 | $366.41 | 23,434.0000 | 134,684,000 | 0.21% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 220 | $365.56 | 23,484.0000 | 134,684,000 | 0.93% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 199 | $364.83 | 23,704.0000 | 134,684,000 | 0.83% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 47 | $363.55 | 23,903.0000 | 134,684,000 | 0.20% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 73 | $362.38 | 23,950.0000 | 134,684,000 | 0.30% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 98 | $361.45 | 24,023.0000 | 134,684,000 | 0.41% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 155 | $360.22 | 24,121.0000 | 134,684,000 | 0.64% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 85 | $359.14 | 24,276.0000 | 134,684,000 | 0.35% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 123 | $358.18 | 24,361.0000 | 134,684,000 | 0.50% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 96 | $357.17 | 24,484.0000 | 134,684,000 | 0.39% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 41 | $356.09 | 24,580.0000 | 134,684,000 | 0.17% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 42 | $355.16 | 24,621.0000 | 134,684,000 | 0.17% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 39 | $353.95 | 24,663.0000 | 134,684,000 | 0.16% | 0.00% |
| Jan. 11, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Common Stock | 3800 | $0.00 | 24,702.0000 | 134,684,000 | 18.18% | 0.00% |
| Oct. 1, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Common Stock | 2851 | $0.00 | 26,861.0000 | 137,348,000 | 11.87% | 0.00% |
| Oct. 1, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Common Stock | 3108 | $0.00 | 24,010.0000 | 137,348,000 | 14.87% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 180 | $448.77 | 26,510.0000 | 137,348,000 | 0.67% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 249 | $449.79 | 26,261.0000 | 137,348,000 | 0.94% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 541 | $450.81 | 25,720.0000 | 137,348,000 | 2.06% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 332 | $451.86 | 25,388.0000 | 137,348,000 | 1.29% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 668 | $452.69 | 24,720.0000 | 137,348,000 | 2.63% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 329 | $453.77 | 24,391.0000 | 137,348,000 | 1.33% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 244 | $454.84 | 24,147.0000 | 137,348,000 | 1.00% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 73 | $455.82 | 24,074.0000 | 137,348,000 | 0.30% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 147 | $457.43 | 23,927.0000 | 137,348,000 | 0.61% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 3 | $457.64 | 23,924.0000 | 137,348,000 | 0.01% | 0.00% |
| Oct. 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 682 | $449.99 | 23,242.0000 | 137,348,000 | 2.85% | 0.00% |
| Oct. 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 810 | $450.63 | 22,432.0000 | 137,348,000 | 3.49% | 0.00% |
| Oct. 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 215 | $454.37 | 20,902.0000 | 137,348,000 | 1.02% | 0.00% |
| Oct. 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 417 | $453.51 | 21,117.0000 | 137,348,000 | 1.94% | 0.00% |
| Oct. 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 898 | $451.76 | 21,534.0000 | 137,348,000 | 4.00% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 56 | $447.92 | 26,690.0000 | 137,348,000 | 0.21% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 115 | $446.53 | 26,746.0000 | 137,348,000 | 0.43% | 0.00% |
| Aug. 19, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 45 | $461.74 | 20,902.0000 | 127,651,000 | 0.21% | 0.00% |
| Aug. 19, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 260 | $459.59 | 21,252.0000 | 127,651,000 | 1.21% | 0.00% |
| Aug. 19, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 231 | $458.27 | 21,512.0000 | 127,651,000 | 1.06% | 0.00% |
| Aug. 19, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 338 | $457.26 | 21,743.0000 | 127,651,000 | 1.53% | 0.00% |
| Aug. 19, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 276 | $455.41 | 22,081.0000 | 127,651,000 | 1.23% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 12 | $455.82 | 22,357.0000 | 127,651,000 | 0.05% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 241 | $454.84 | 22,369.0000 | 127,651,000 | 1.07% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 543 | $454.04 | 22,610.0000 | 127,651,000 | 2.35% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 329 | $452.96 | 23,153.0000 | 127,651,000 | 1.40% | 0.00% |
| Aug. 15, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | A | Common Stock | 2851 | $0.00 | 23,753.0000 | 127,651,000 | 13.64% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 103 | $451.99 | 23,482.0000 | 127,651,000 | 0.44% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 39 | $450.92 | 23,585.0000 | 127,651,000 | 0.17% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 90 | $449.92 | 23,624.0000 | 127,651,000 | 0.38% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 39 | $447.98 | 23,714.0000 | 127,651,000 | 0.16% | 0.00% |
| Aug. 19, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | EVP Chief R&D | S | Common Stock | 305 | $461.01 | 20,947.0000 | 127,651,000 | 1.44% | 0.00% |
| March 24, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 5445 | $300.00 | 20,902.0000 | 127,651,000 | 20.67% | 0.00% |
| March 24, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Common Stock | 5445 | $42.22 | 26,347.0000 | 127,651,000 | 26.05% | 0.00% |
| March 21, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 4321 | $285.00 | 20,902.0000 | 127,651,000 | 17.13% | 0.00% |
| March 24, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Stock Option (right to buy) | 5445 | $0.00 | 0.0000 | 127,651,000 | 100.00% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 116 | $245.26 | 27,058.0000 | 127,651,000 | 0.43% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 14137 | $0.00 | 27,780.0000 | 127,651,000 | 103.62% | 0.01% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 213 | $242.37 | 27,567.0000 | 127,651,000 | 0.77% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 235 | $243.36 | 27,332.0000 | 127,651,000 | 0.85% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 158 | $244.41 | 27,174.0000 | 127,651,000 | 0.58% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 48 | $246.18 | 27,010.0000 | 127,651,000 | 0.18% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 5 | $247.35 | 27,005.0000 | 127,651,000 | 0.02% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 1 | $248.36 | 27,004.0000 | 127,651,000 | 0.00% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 583 | $243.13 | 26,421.0000 | 127,651,000 | 2.16% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 273 | $244.43 | 26,148.0000 | 127,651,000 | 1.03% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 117 | $245.53 | 26,031.0000 | 127,651,000 | 0.45% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 147 | $239.25 | 25,884.0000 | 127,651,000 | 0.56% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 343 | $240.92 | 25,541.0000 | 127,651,000 | 1.33% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 198 | $241.60 | 25,343.0000 | 127,651,000 | 0.78% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 120 | $242.70 | 25,223.0000 | 127,651,000 | 0.47% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Stock Option (right to buy) | 7819 | $0.00 | 7,819.0000 | 127,651,000 | 9999.99% | 0.01% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 51 | $236.51 | 14,527.0000 | 127,651,000 | 0.35% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 40 | $238.33 | 14,487.0000 | 127,651,000 | 0.28% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 41 | $239.18 | 14,446.0000 | 127,651,000 | 0.28% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 91 | $240.32 | 14,355.0000 | 127,651,000 | 0.63% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 149 | $241.51 | 14,206.0000 | 127,651,000 | 1.04% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 352 | $242.44 | 13,854.0000 | 127,651,000 | 2.48% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 142 | $243.23 | 13,712.0000 | 127,651,000 | 1.02% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 69 | $244.11 | 13,643.0000 | 127,651,000 | 0.50% | 0.00% |
| Feb. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Restricted Stock Units | 1908 | $0.00 | 1,908.0000 | 127,651,000 | 50.00% | 0.00% |
| Feb. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Common Stock | 1908 | $0.00 | 14,578.0000 | 127,651,000 | 15.06% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 107 | $257.99 | 12,750.0000 | 127,651,000 | 0.83% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 349 | $252.50 | 15,430.0000 | 127,651,000 | 2.21% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 80 | $259.10 | 12,670.0000 | 127,651,000 | 0.63% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 386 | $253.37 | 15,044.0000 | 127,651,000 | 2.50% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 258 | $254.35 | 14,786.0000 | 127,651,000 | 1.71% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 110 | $255.56 | 14,676.0000 | 127,651,000 | 0.74% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 126 | $256.29 | 14,550.0000 | 127,651,000 | 0.86% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 60 | $257.51 | 14,490.0000 | 127,651,000 | 0.41% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 77 | $258.07 | 14,413.0000 | 127,651,000 | 0.53% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 27 | $259.72 | 14,386.0000 | 127,651,000 | 0.19% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 49 | $260.57 | 14,337.0000 | 127,651,000 | 0.34% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 60 | $261.45 | 14,277.0000 | 127,651,000 | 0.42% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 27 | $263.33 | 14,250.0000 | 127,651,000 | 0.19% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 32 | $264.87 | 14,218.0000 | 127,651,000 | 0.22% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 862 | $250.11 | 13,356.0000 | 127,651,000 | 6.06% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 306 | $250.73 | 13,050.0000 | 127,651,000 | 2.29% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 110 | $251.60 | 12,940.0000 | 127,651,000 | 0.84% | 0.00% |
| Feb. 13, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 3109 | $0.00 | 15,779.0000 | 127,651,000 | 24.54% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 83 | $256.05 | 12,857.0000 | 127,651,000 | 0.64% | 0.00% |
| Jan. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Common Stock | 25000 | $88.95 | 65,262.0000 | 127,651,000 | 62.09% | 0.02% |
| Jan. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Performance Stock Option 2015 (right to buy) | 25000 | $0.00 | 0.0000 | 127,651,000 | 100.00% | 0.02% |
| Jan. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Stock Option (right to buy) | 23876 | $0.00 | 0.0000 | 127,651,000 | 100.00% | 0.02% |
| Jan. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Common Stock | 23876 | $88.95 | 40,262.0000 | 127,651,000 | 145.71% | 0.02% |
| Jan. 27, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 52592 | $285.00 | 12,670.0000 | 127,651,000 | 80.59% | 0.04% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 426 | $250.08 | 17,405.0000 | 128,590,000 | 2.39% | 0.00% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 1 | $255.80 | 16,386.0000 | 128,590,000 | 0.01% | 0.00% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 140 | $254.37 | 16,387.0000 | 128,590,000 | 0.85% | 0.00% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 100 | $252.94 | 16,527.0000 | 128,590,000 | 0.60% | 0.00% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 778 | $251.68 | 16,627.0000 | 128,590,000 | 4.47% | 0.00% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 186 | $248.99 | 17,831.0000 | 128,590,000 | 1.03% | 0.00% |
| Dec. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 121 | $247.48 | 18,017.0000 | 128,590,000 | 0.67% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 30 | $247.77 | 19,790.0000 | 128,590,000 | 0.15% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 945 | $251.42 | 18,235.0000 | 128,590,000 | 4.93% | 0.00% |
| Nov. 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 3434 | $0.00 | 19,820.0000 | 128,590,000 | 20.96% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 97 | $252.27 | 18,138.0000 | 128,590,000 | 0.53% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 246 | $249.60 | 19,544.0000 | 128,590,000 | 1.24% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 364 | $250.68 | 19,180.0000 | 128,590,000 | 1.86% | 0.00% |
| Oct. 8, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 96 | $0.00 | 16,386.0000 | 128,590,000 | 0.59% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 348 | $229.06 | 17,712.0000 | 124,906,000 | 1.93% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 398 | $229.93 | 17,314.0000 | 124,906,000 | 2.25% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 129 | $231.59 | 17,185.0000 | 124,906,000 | 0.75% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 283 | $232.54 | 16,902.0000 | 124,906,000 | 1.65% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 151 | $233.53 | 16,751.0000 | 124,906,000 | 0.89% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 219 | $235.19 | 16,290.0000 | 124,906,000 | 1.33% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 242 | $234.66 | 16,509.0000 | 124,906,000 | 1.44% | 0.00% |
| June 24, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 4295 | $0.00 | 18,393.0000 | 124,906,000 | 30.47% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 78 | $221.71 | 18,315.0000 | 124,906,000 | 0.42% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 17 | $224.17 | 18,298.0000 | 124,906,000 | 0.09% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 24 | $225.55 | 18,274.0000 | 124,906,000 | 0.13% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 45 | $226.82 | 18,229.0000 | 124,906,000 | 0.25% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 169 | $228.30 | 18,060.0000 | 124,906,000 | 0.93% | 0.00% |
| March 1, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 4751 | $0.00 | 14,098.0000 | 124,906,000 | 50.83% | 0.00% |
| March 1, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Stock Option (right to buy) | 9279 | $0.00 | 9,279.0000 | 124,906,000 | 9999.99% | 0.01% |
| Feb. 28, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 1 | $158.09 | 9,347.0000 | 124,906,000 | 0.01% | 0.00% |
| Feb. 27, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Common Stock | 1908 | $0.00 | 9,921.0000 | 124,906,000 | 23.81% | 0.00% |
| Feb. 28, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 247 | $154.54 | 9,674.0000 | 124,906,000 | 2.49% | 0.00% |
| Feb. 28, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 194 | $155.45 | 9,480.0000 | 124,906,000 | 2.01% | 0.00% |
| Feb. 28, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 115 | $156.38 | 9,365.0000 | 124,906,000 | 1.21% | 0.00% |
| Feb. 28, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 17 | $157.30 | 9,348.0000 | 124,906,000 | 0.18% | 0.00% |
| Feb. 27, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | M | Restricted Stock Units | 1908 | $0.00 | 3,816.0000 | 124,906,000 | 33.33% | 0.00% |
| Feb. 16, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 672 | $148.24 | 8,169.0000 | 124,906,000 | 7.60% | 0.00% |
| Feb. 15, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | A | Common Stock | 4295 | $0.00 | 9,321.0000 | 124,906,000 | 85.46% | 0.00% |
| Feb. 16, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 480 | $147.50 | 8,841.0000 | 124,906,000 | 5.15% | 0.00% |
| Feb. 16, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Garg Pushkal | CMO & EVP Dev & Med Affairs | S | Common Stock | 156 | $149.03 | 8,013.0000 | 124,906,000 | 1.91% | 0.00% |